Skip to content Skip to sidebar Skip to footer
Home / Wound Healing Dressings and Drug Delivery Systems a Review

Wound Healing Dressings and Drug Delivery Systems a Review

Post a Comment

Open admission peer-reviewed chapter

Delivery Systems in Wound Healing and Nanomedicine

Submitted: December 2nd, 2015 Reviewed: April 18th, 2016 Published: October 12th, 2016

DOI: 10.5772/63763

From the Edited Book

Wound Healing

Edited by Vlad Adrian Alexandrescu

IntechOpen

IntechOpen Downloads

2,135

Total Chapter Downloads on intechopen.com

Abstract

Introduction: Delivery systems in nanomedicine contribute to the improvements in wound healing, tissue regeneration, and anticancer pharmacological fields. Although diverse wound dressings have been used in wound intendance treatments, at that place is a great challenge in the wound management of ulcers, trauma, chronic wounds, and astringent injury and burns, peculiarly infected wounds.

Keywords

  • wound healing
  • delivery system
  • wound dressing
  • skin regeneration
  • biomaterials

one. Introduction

Nanomedicine has had a significant impact on delivery system development for pharmacological fields that include controlled‐release wound dressings and biocompatible nanocarriers for biomedical applications [1]. As the largest organ in the homo body, skin gives the body protection, but in and then doing sustains a multifariousness of skin wounds that require firsthand repair process [ii]. Modern wound dressings accept been under development for decades. Although there are a broad array of wound dressings, ointments, and medical devices for clinical utilise, the time‐consuming process of wound direction is mainly restricted to wound repair rather than regeneration, which are two distinct definitions [iii]. The key problem of skin regeneration is how to restore the native structure and function of the injured organ, including claret capillaries. Recently, biomaterial carriers in nanomedicine have shifted the focus from patient survival to quality of skin regeneration in terms of function, scar reduction, and improved aesthetics for reconstruction surgeries and burns [4]. In the formats of wound dressings and transdermal formulations, delivery systems have been applied to accelerate wound healing and to promote tissue regeneration, equally well as to care for peel cancers using nanomedicine.

There are different circumstances in which people may need wound intendance and management. To run across the challenges of wound treatments for acute wounds and chronic wounds, such as large‐area skin loss, burns, ulcers (pressure, diabetic, neuropathic, or ischemic), trauma, and specially infected wounds, which are by and large acquired by microbes [v], the accurate delivery of antimicrobial agents is attracting much attention from researchers [half-dozen–eight]. In add-on to antimicrobial wound dressing, delivery systems of bioactive proteins, such equally peptides and growth factors (platelet‐derived growth factor, PDGF; endothelial growth cistron, EGF; and fibroblast growth factor 2, FGF2 or bFGF), accept demonstrated their promising effects in wound healing [9]. Cell therapy, including stalk cell strategy, provides a novel therapeutic approach to wound healing [10]. Interestingly, mesenchymal stem cells (MSCs) and adipose‐derived stem cells (ASCs) have emerged as a new approach in peel tissue engineering to accelerate wound closure, which would be of enormous benefit particularly for those wounds experiencing delayed healing in patients with diabetes and elderly [11, 12]. Gene delivery systems for wound healing have been also adult to transfer deoxyribonucleic acid (Dna) and ribonucleic acid (RNA) to wound sites [13, xiv]. The regulations of delivery systems in wound healing can exist complicated and vary profoundly depending on the specific biomaterials and scaffolds, as well as the clinical employ in item [fifteen]. In the commercialization of commitment wound healing systems, developmental and regulatory challenges are greater than in normal wound dressing and wound healing products. The biomaterials and scaffolds used in delivery systems accept advantage of unlike structures, chemic parameters, and sources and so may crave more rigorous development and regulation.

This chapter reviews biomaterials and scaffolds used in the design, characterization, and evaluation of delivery systems for wound healing, which include delivering antimicrobial drugs, combinations of proteins (growth factors and peptides), cells, and genes (Figure 1). Specific examples of awarding are summarized. Regenerations of skin tissues and reconstructions of claret capillaries in the wound care procedure are covered. In addition, the regulatory considerations for delivery systems in the wound healing field are also explored.

Effigy 1.

Delivery systems in wound healing.

Advertisement

2. Drug delivery arrangement in wound healing

Chronic wounds and infected wounds currently pose a significant burden worldwide. Drug delivery systems (DDS) in wound healing that release antimicrobial and anti‐inflammatory drugs represent a swell opportunity to prevent infections or raise the effectiveness of current commercial drugs. Many biocompatible biomaterials have been extensively investigated to deliver drugs into wound beds and to improve wound healing. Pregnant efforts have been made to develop DDS using different types of biomaterials, such as polymeric microspheres and nanospheres, lipid nanoparticles, nanofibrous structures, hydrogels, and scaffolds [sixteen].

2.1. Delivery of antibiotics

Wound healing is a complex process that often requires treatment with antibiotics. To optimize and amend the usage of currently available antibiotics, DDS of antibiotics have attracted much attending. Antibody drugs used in delivery systems for wound healing are cefazolin [17], gentamicin sulfate [6], ceftazidime pentahydrate [xviii], ciprofloxacin [19], gentamicin [20], doxycycline hyclate [21], and the anti‐inflammatory drug diclofenac [20]. Various biodegradable polymeric scaffolds (electrospun nanofibers, microspheres, composites, and films) were investigated for antibody delivery systems, including electrospun nanofibers of poly(lactide‐co‐glycolide) (PLAGA) [17], composites of a polyglyconate core and a porous poly(dl‐lactic‐co‐glycolic acrid) shell [18], chitosan (CS)‐gelatin composite films [nineteen], a 3‐dimensional (3D) polycaprolactone‐tricalcium phosphate (PCL‐TCP) mesh [6], bacterial cellulose (BC) membranes grafted with RGDC peptides (R for arginine, G for glycine, D for aspartic acid, C for cysteine) [xx], poly(vinyl alcohol) (PVA) microspheres sandwiched poly(iii‐hydroxybutyric acrid) (PHB) electrospun fibers [21], and β‐cyclodextrin‐conjugated hyaluronan hydrogels [22].

Antibiotic agents used in wound healing typically incur agin effects (due east.g., nephrotoxicity for vancomycin, cytotoxicity for ciprofloxacin, and hemolysis for antimicrobial polymers). Loading of antibiotics inside polymeric vesicles could attenuate side effects, which has been demonstrated recently [23]. Li et al. reported a general strategy to construct a bacterial strain‐selective delivery system for antibiotics based on responsive polymeric vesicles. That was in response to enzymes, including penicillin G amidase (PGA) and β‐lactamase (Bla) that are closely associated with drug‐resistant bacterial strains. A sustained release of antibiotics enhanced stability and reduced side effects. The results demonstrated that methicillin‐resistant Staphylococcus aureus ( S. aureus ) (MRSA)‐triggered release of antibiotics from Bla‐degradable polymeric vesicles in vitro inhibited MRSA growth, and enhanced wound healing in an in vivo murine model.

2.two. Delivery of silver

To solve the problem of the increased prevalence and growth of multidrug‐resistant bacteria, silver is used to reduce and eliminate wound infections using methodologies that limit the ability of bacteria to evolve into further antibiotic‐resistant strains. In recent decades, the developments of silver (colloidal silver solution, silver proteins, silver salts, silverish sulfadiazine (SSD) and nanosilver)‐containing wound dressings for healing promotion and infection reduction have provided promising approaches [24]. The main synthesis approaches of silvery monocrystalline silver (nanosilver or silver nanoparticle) include chemical reduction, microorganism reduction, microwave‐assisted photochemical reduction, and light amplification by stimulated emission of radiation ablation. Antibacterial wound dressings in the formats of AgNP‐embedded poly(vinyl pyrrolidone) (PVP) hydrogels were prepared by γ‐irradiation at various doses: 25, 35, and 45 kGy [25]. Antibacterial tests showed that the one and 5 mM AgNP‐embedded PVP hydrogels were constructive, with 99.99% bactericidal activity at 12 and 6 h, respectively. A gamma‐irradiated PVA/nanosilver hydrogel was also adult for potential employ in burn dressing applications [26]. Interestingly, the wound healing activity of 0.ane% west/w AgNPs in Pluronic F127 gels was enhanced to a considerable extent [27]. A new type of high surface area metal silver in the grade of highly porous silverish microparticles (AgMPs) was studied [28]. Polylactic acid (PLA) nanofibers were successfully loaded with either highly porous AgMPs or AgNPs. A fake three‐dimensional (3D) coculture system was designed to evaluate human epidermal keratinocytes and South. aureus bacteria on the wound dressings. PLA nanofibers containing highly porous AgMPs exhibited steady argent ion release at a greater charge per unit of release than nanofibers containing AgNPs.

Due to its antimicrobial activity, good coagulation and immunostimulating activities, chitosan is one of the native polymers chosen to control infection and heighten wound healing. Chitosan‐based wound dressings can be gels, microparticles or nanoparticles, sponges and films [29]. Sacco et al. combined the two antimicrobial agents, silver and chitosan, to develop a silvery‐containing antimicrobial membrane based on chitosan‐tripolyphosphate (TPP) hydrogel for wound treatments. Based on the slow diffusion of TPP, the macroscopic chitosan hydrogels were obtained that included AgNPs stabilized by a lactose‐modified chitosan. Too the good bactericidal properties of the cloth, the biocompatibility assays on keratinocytes (HaCaT) and fibroblasts (NIH‐3T3) cell lines did non evidence to have any harmful effects on the viability of cells using the MTT [one‐(4,five‐dimethylthiazol‐2‐yl)‐3,5‐diphenylformazan] method [8]. Chitin was as well used to class the composite scaffolds with nanosilver. These chitin/nanosilver composites were found to be bactericidal against S. aureus and Escherichia coli ( E. coli ) with adept blood‐clotting ability [30].

Bioelectric wound dressing can also deliver silvery to wound beds. Pseudomonas aeruginosa (P. aeruginosa) is a mutual bacterium associated with chronic wound infection. An US Food and Drug Administration (FDA)‐approved wireless electroceutical dressing (WED), which in the presence of conductive wound exudate is activated to generate an electric field (0.3–0.9 Five), was investigated to test its anti‐biofilm properties using a pathogenic P. aeruginosa strain PAO1. WED markedly disrupted biofilm integrity in a setting where normal silverish dressing was ineffective. Biofilm thickness and number of alive bacterial cells were decreased in the presence of Midweek considering WED served a spontaneous source of reactive oxygen species [31].

two.3. Delivery of other drugs

As well silver, other drugs tin can be used to improve wound healing, for example, the anti‐scar drug astragaloside Four [32]. In a rat full‐skin excision model, the**** in vivo regulation of 9% astragaloside Four‐based solid lipid nanoparticles‐gel enhanced the migration and proliferation of keratinocytes, increased drug uptake on fibroblasts in vitro ( P < 0.01) through the caveolae endocytosis pathway, and inhibited scar germination in vivo by increasing wound closure rate ( P < 0.05) and by contributing to angiogenesis and collagen regular organization.

Different from most antibiotics that select for resistant bacteria, curcumin acts using multiple mechanisms. Curcumin (diferuloylmethane) is a bioactive and major phenolic component of turmeric derived from the rhizomes of Curcuma longa linn . Attributable to its antioxidant and anti‐inflammatory properties, curcumin plays a significant beneficial and pleiotropic regulatory office not only in cancers, cardiovascular disease, Alzheimer's disease, inflammatory disorders, and neurological disorders merely also in wound healing because of its innate antimicrobial properties. Withal, the clinical implication of native curcumin is hindered due to depression solubility, physicochemical instability, poor bioavailability, rapid metabolism, and poor pharmacokinetics, but these issues can be overcome past efficient delivery systems [33]. A biodegradable sponge, made from chitosan (CS) and sodium alginate (SA) with water uptake ability ranging between 1000 and 4300%, was adult to deliver curcumin as a wound dressing material up to 20 days. The in vivo creature examination using SD rats showed that this CS/SA sponge had a better result than cotton gauze, and adding curcumin into the sponge enhanced the therapeutic healing effect and improved collagen organisation [34]. Curcumin nanoparticles (Curc‐np) with an average diameter of 222 ± 14 nm were synthesized [35]. Curc‐np correspond a significant advance for reducing bacterial load. They tin inhibit in vitro growth of methicillin‐resistant S. aureus (MRSA) and P. aeruginosa in dose‐dependent fashion, and and so may represent a novel topical antimicrobial and wound healing adjuvant for infected burn wounds and other cutaneous injuries. Bacterial cellulose (BC) can be used for drug loading and controlled release [36]. The topical or transdermal drug delivery systems of two model drugs (lidocaine hydrochloride and ibuprofen) were developed. Diffusion studies with Franz cells showed that the incorporation of lidocaine hydrochloride in BC membranes provided lower permeation rates than those obtained with the conventional formulations [37].

At that place is a high mortality in patients with diabetes and severe pressure ulcers, resulting from the reduced neovascularization caused by the impaired activity of the transcription gene hypoxia‐inducible factor‐1 alpha (HIF‐1α). To improve HIF‐1α activity, Duscher et al. developed the drug delivery system of an FDA‐approved small molecule deferoxamine (DFO), which is an iron chelator that increases HIF‐1α transactivation in diabetes past preventing iron‐catalyzed reactive oxygen stress [38]. The animate being study on a pressure‐induced ulcer model in diabetic mice showed a significantly improved wound healing using the transdermal delivery of DFO. DFO‐treated wounds demonstrated increased collagen density, improved neovascularization, and reduction of free radical formation, leading to decreased prison cell decease.

Advertizing

three. Bioactive protein delivery systems in wound healing

Wound healing in pare is an evolutionarily conserved, complex, multicellular process, which is executed and regulated by an as circuitous signaling network involving numerous growth factors, cytokines, and chemokines [39]. Growth factors are soluble secreted proteins capable of affecting a diversity of cellular processes important for tissue regeneration. However, the application of growth factors in clinics remains express due to lack of good delivery systems and carriers. Recently, biomaterial carriers and sophisticated delivery systems such as nanoparticles and nanofibers for delivery of growth factors and peptides related in wound healing are a main focus in this research surface area [40].

3.ane. Delivery of growth factors

EGF, PDGF, FGF2, keratinocyte growth factor (KGF) [41], transforming growth factor‐β (TGF‐β), insulin‐like growth factor (IGF), vascular endothelial growth factor (VEGF), granulocyte macrophage colony stimulating gene (GM‐CSF), and connective tissue growth gene (CTGF) are the master growth factors correlated with the wound healing process of skin [16]. Growth factors usually have short half‐life fourth dimension leading to a rapid deactivation at local wound beds in the torso and resulting in a low efficacy. In gild to enhance the efficacy of growth cistron commitment systems, some bioactive and biodegradable matrixes including extracellular matrixes, accept been used every bit carriers [42].

EGF is i of the most common growth factors used for treating skin wounds. Succinoylated dextrin (~85,000 g/mol; ~19 mol% succinoylation), a clinically well‐tolerated polymer, was used to deliver EGF and led to sustained release of free recombinant human EGF over time (52.7% release afterwards 168 h) [43]. Using a layer‐past‐layer assembly technique, EGF was successfully encapsulated using poly(acrylic acid) (PAA)‐modified polyurethane (PU) films [44] or chitosan and alginate films [45]. Johnson and Wang treated the full‐thickness wounded mice with a heparin‐binding epidermal growth factor coacervate delivery system, and the results exhibited the enhanced migration of keratinocytes with retained proliferative potential, forming a confluent layer for regained barrier function within seven days [46]. Chitosan‐based gel formulations containing egg yolk oil and EGF are amend alternatives compared to Silverdin® (1% silver sulfadiazine), given their significant difference ( P < 0.05) treating wounds in Wistar rats [47]. Since the healing rate of wound is an important factor influencing the event of clinical treatments, too as a crucial footstep in burn wound treatment, and the quality of wound healing has a direct bearing on the life quality of patients, FGF2 clearly has clinical efficacy in a variety of wound managements [48]. Pare flap survival is a major challenge in reconstructive plastic surgery. A sustained commitment system of FGF2 using heparin‐conjugated fibrin was used to improve pare flap survival significantly in a rat animal model [49]. A delivery organisation composed of fibrin hydrogels doped with bFGF‐loaded double emulsion increased the proliferation of endothelial cells compared to sham controls, indicating that the released bFGF was bioactive [50]. An injectable commitment system of PDGF using two‐component polyurethane scaffolds was reported to achieve a sustained release for upward to 21 days. The in vitro bioactivity of the released PDGF was largely preserved by a lyophilized pulverization. The presence of PDGF attracted both fibroblasts and mononuclear cells, significantly accelerating the degradation of the polymer and enhancing the formation of new granulation tissue every bit early on every bit day 3 [51]. Hyaluronan‐based porous nanoparticles were besides investigated for the delivery of PDGF [52]. Recombinant human stromal jail cell‐derived cistron‐i (SDF‐ane), a naturally occurring chemokine that is speedily overexpressed in response to tissue injury, was delivered in an alginate gel to accelerate wound closure and reduce scar formation [53]. SDF‐one delivery systems were evaluated using an acute surgical Yorkshire pig model. Wounds treated with SDF‐ane protein ( n = 10) and plasmid ( n = six)‐loaded alginate patches healed faster than the sham ( n = four) or control ( northward = 4). At mean solar day 9, SDF‐1‐treated wounds significantly accelerated wound closure (55.0 ± 14.3% healed) compared to nontreated controls (8.2 ± half-dozen.0%, p < 0.05).

Recently, it has been increasingly recognized that biodegradable and biocompatible scaffolds incorporated with multiple growth factors might serve every bit the most promising medical devices for skin tissue regeneration. Beyond drug delivery, BC hydrogel is used to deliver bFGF, EGF, and KGF with modifications of different extracellular matrices (ECMs; collagen, elastin, and hyaluronan) [54]. In vitro and in vivo evaluation of the applicability of a dextran hydrogel loaded with chitosan microparticles (255 ± 0.nine μm) containing EGF and VEGF were performed, and they accelerated wound healing [55]. Moreover, the histological analysis revealed the absenteeism of reactive or granulomatous inflammatory reaction in skin lesions. Multiple epidermal consecration factors (EIF), such equally EGF, insulin, hydrocortisone, and retinoic acid (RA), were prepared for blended and cadre‐shell electrospinnings with gelatin (gel) and poly(l‐lactic acid)‐co‐poly‐(e‐caprolactone) (PLLCL) solutions [56]. An initial 44.9% burst release from EIF composite electrospun nanofibers was observed over a period of 15 days. The epidermal differentiation potential of adipose‐derived stem cells (ADSCs) was used to evaluate the scaffolds prepared either by cadre‐shell spinning or by blend spinning. Afterward fifteen days of cell civilization, the proliferation of ADSCs on EIF‐encapsulated core‐crush nanofibers was the highest. Moreover, a college percentage of ADSCs were differentiated to epidermal lineages on EIF‐encapsulated core‐shell nanofibers compared to the cell differentiation of EIF‐blended nanofibers, and this can be attributed to the sustained release of EIF from the core‐beat nanofibers. A method for blanket commercially available nylon wound dressings using the layer‐by‐layer process was utilized to control the release of VEGF165 and PDGF‐BB [57]. Animal evaluation was performed using a db/db mouse model of chronic wound healing. This combination delivery organisation promotes significant increases in the germination of granulation tissue and/or cellular proliferation when compared to dressings utilizing single growth factor therapeutics.

3.ii. Delivery of peptides

Current therapeutic regiments of wounded patients are static and more often than not rely on matrices, gels, and engineered skin tissue. Accordingly, there is a need to design next‐generation grafting materials to enable biotherapeutic spatiotemporal targeting from clinically canonical matrices. Peptides are practiced candidates for controlling wound infections. A drug carrier system was designed for delivering an insect metalloproteinase inhibitor (IMPI) drug to enable treatment of chronic wound infections [58]. Poly(lactic‐co‐glycolic acrid) (PLGA) supplies lactate that accelerates neovascularization and promotes wound healing. Delivery systems of LL37 peptide encapsulated in PLGA nanoparticles (PLGA‐LL37 NP) were evaluated in full‐thickness excisional wounds. A significantly higher collagen deposition, re‐epithelialized and neovascularized composition were establish in PLGA‐LL37 NP‐treated group. In vitro , PLGA‐LL37 NP induced enhanced prison cell migration but had no consequence on the metabolism and proliferation of keratinocytes. Interestingly, it displayed antimicrobial activity on E. coli [59]. CM11 peptide (WKLFKKILKVL‐NHtwo) (128 mg/50), a short cecropin‐melittin hybrid peptide, was delivered by an alginate sulfate‐based hydrogel as the antimicrobial wound dressing, and its healing effects were tested on skin infections caused by MRSA (200 μL, 3 × 108CFU/mL) in a mouse model [sixty]. During eight‐solar day period, the 2% mupirocin treatment group and hydrogel containing peptide handling groups showed like levels of wound healing.

Advertisement

four. Cell delivery systems in wound healing

Wound healing involves the coordinated efforts of several cell types, including keratinocytes, fibroblasts, endothelial cells, macrophages, and platelets. The migration, infiltration, proliferation, and differentiation of these cells will culminate in an inflammatory response, the formation of new tissue and ultimately wound closure [39]. Cell‐based therapies for wound repair are limited past inefficient delivery systems that fail to protect cells from astute inflammatory environments [61]. Wound dressing of cells laden in biomaterials on wound surfaces might not effectively and timely exert functions on deep or chronic wounds, where insufficient blood supply presents. Therefore, jail cell delivery systems are the principal focus in the jail cell‐based therapeutic field. Jail cell, including stem cells and other cells, delivered wound dressings accept recently shown great promise for accelerating wound healing and reducing scar formation.

4.1. Stem cells

Stalk cell therapy offers a promising new technique for aiding in wound healing; notwithstanding, current findings show that stalk cells typically die and/or migrate from the wound site, greatly decreasing the efficacy of the treatment. Most stalk cells studied in wound healing commitment systems are mesenchymal stalk cells (MSCs), endothelial progenitor cells (EPCs), adipose‐derived stem cells (ASCs), umbilical cord perivascular cells (UCPCs), and circulating angiogenic cells (CACs). MSCs have been shown to improve tissue regeneration in several preclinical and clinical trials [62]. MSCs from various sources, such as bone marrow and adipose tissue, have been reported in the delivery systems for wound healing [10, 63].

A 3D membrane (FBMSC‐CMM) from a freeze‐stale os marrow mesenchymal stalk cells‐conditioned medium (FBMSC‐CM) can hold over 80% of the paracrine factors, which could significantly accelerate wound healing and enhance the neovascularization too as epithelialization through strengthening the trophic factors in the wound bed [11]. Scaffolds strongly influence key parameters of stem jail cell commitment, such as seeding efficiency, cellular distribution, attachment, survival, metabolic activity, and paracrine release [64]. Pullulan was used to form a composite with collagen hydrogel for the delivery of MSCs into wounds [65]. Hydrogels induced MSC secretions of angiogenic cytokines and expression of transcription factors associated with the maintenance of pluripotency and cocky‐renewal (Oct4, Sox2, Klf4) when compared to MSCs grown in standard weather. Engrafted MSCs were found to differentiate into fibroblasts, pericytes, and endothelial cells simply did not contribute to the epidermis. Wounds treated with MSC‐seeded hydrogels demonstrated significantly enhanced angiogenesis, which was associated with increased levels of VEGF.

There are other kinds of stalk cells that have been used in combination with 3D scaffolds every bit a promising approach in the field of regenerative medicine. For instance, human umbilical cord perivascular cells (HUCPVC) [66], amniotic fluid‐derived stem cells (AFSs) [67], EPCs [68], and circulating angiogenic cells (CACs). CACs are known as early on EPCs and are isolated from the mononuclear cell fraction of peripheral blood, and provide a potential topical treatment for nonhealing diabetic human foot ulcers. A scaffold fabricated from type 1 collagen facilitates topical cell delivery of CACs to a diabetic rabbit ear wound (alloxan‐induced ulcer). Increased angiogenesis and increased per centum wound closure were observed with the treatment of collagen and collagen seeded with CSCs [69].

Compared to MSCs and EPCs, adipose‐derived mesenchymal stem cells (ASCs) represent an even more highly-seasoned source of stem cells considering of their abundance and accessibility. ASCs are autologous, non‐immunogenic, plentiful, and hands obtained [seventy]. An acellular dermal matrix (ADM) scaffold fabricated from cadaveric skins of human donors (AlloDerm, LifeCell Corp., Branchburg, NJ, Us) was served as a carrier for the delivery of ASCs [12]. ASCs‐ADM grafts secreted various cytokines, including VEGF, HGF, TGFβ, and bFGF. Novel technology and biocompatible biomaterials take been applied for stem prison cell delivery. A silk fibroin‐chitosan (SFCS) scaffold serving every bit a delivery vehicle for man adipose‐derived stem cells (ASCs) was evaluated in a murine soft tissue injury model [71]. Microvessel density at wound bed biopsy sites at two weeks postoperative was significantly college in the ASC‐SFCS group vs. SFCS alone (vii.v ± ane.one vs. 5.1 ± 1.0 blood vessels per high‐ability field). A newly developed thermoresponsive poly(ethylene) glycol (PEG)‐hyaluronic acid (HA) hybrid hydrogel with multiple acrylate functional groups provides an efficient delivery dressing organization for human being adipose‐derived stem cells (hADSCs) [72]. Although cellular proliferation was inhibited, cellular secretion of growth factors, such as VEGF and PDGF production, increased over 7 days, whereas IL‐2 and IFNγ release were unaffected. Injectable gelatin microcryogels (GMs) were used to load human ASCs [73]. The results demonstrated the priming furnishings of GMs on the upregulation of stemness genes and improved secretion of growth factors of hASCs for potential augmented wound healing. In a total‐thickness skin wound model in nude mice, multisite injections and dressings of hASC‐laden GMs significantly accelerated the healing compared to gratis stem prison cell injection.

4.2. Other cells

Endothelial cells (ECs), keratinocytes, and fibroblasts are the most studied cells in terms of accelerated wound healing and improved skin tissue regeneration. A growing number of studies signal that endothelial cells (ECs) and endothelial progenitor cells (EPCs) may regulate vascular repair in wound healing via paracrine mechanisms [61]. Using dried reagent patches that incorporate dextran (DEX) and a bulk aqueous phase comprising a cell culture medium containing poly(ethylene) glycol (PEG), Bathany et al. made a micro‐patterned localized commitment of fluorescent molecules and enzymes for cell disengagement [74]. Keratinocytes were delivered to dermal wounds in mice via jail cell‐agglutinative peptides attached to chitosan membranes [75]. Two peptides of 12 or 13 amino acids each that bind to cell surface heparin‐similar receptors (A5G27 and A5G33) were constitute to promote stiff keratinocyte zipper, whereas the one that binds to integrin (A99) was inactive. Recombinant human being collagen III (rhCol‐III) gel was used as a delivery vehicle for cultured autologous skin cells (keratinocytes only or keratinocyte‐fibroblast mixtures) [76]. Its event on the healing of full‐thickness wounds in a porcine wound‐healing model was examined. Two Landrace pigs were used for the study. Fourteen deep dermal wounds were created on the dorsum of each squealer with an viii‐mm biopsy dial. The scaffold enhanced early granulation tissue germination. Interestingly, fibroblast‐containing gel was effectively removed from the wound, whereas gels without cells or with keratinocytes only remained intact.

Advertisement

5. Gene delivery systems in wound healing

Gene commitment is an emerging technology in the field of tissue repair and is being used to promote wound healing. Gene delivery is targeted to develop sustained release, to reduce side effects, and to enable both spatial and temporal control of gene silencing later. For example, chemical modifications were used to stabilize and reduce nonspecific effects of siRNA molecules using constructive delivery [77]. The controlled delivery of nucleic acids (DNA and RNA) to selected tissues remains an inefficient procedure are affected by low transfection efficacy, poor scalability because of varying efficiency with cell type and location, and questionable condom as a result of toxicity issues arising from the typical materials (e.g., viral vectors) and procedures employed. Biocompatible materials, in the formats of micro/nanoparticles, scaffolds, hydrogels and electrospun fibers, made from cationic polymers and lipids, take been used as nonviral vectors, which has attracted much attention recently.

5.i. Viral vectors in factor delivery

Figure 2.

Transgenic overexpression of TGFβ3 decreases fibroblast to myofibroblast differentiation at the site of cutaneous woundingin vivo. (A) and (B) wound sections were stained immunohistochemically for fibroblast (a: vimentin) and myofibroblast (b: SMA) markers subsequently treatment with [a and b(i)] PBS, [a and b(two)] Lnt‐TGFβ3, or [a and b(iii)] Lnt‐mutTGFβ3. (C) Existent‐fourth dimension reverse transcription‐PCR showed that both TGFβ3 awarding groups and the PBS control (north = iv) as well as a significant subtract between the Lnt‐mutTGFβ3 and Lnt‐TGFβ3 treatment groups. PBS, phosphate‐buffered saline; SMA, smooth musculus actin; TGF, transforming growth factor.

The TGFβ family plays a critical regulatory role in repair and coordination of remodeling subsequently cutaneous wounding. TGFβ3 has been implicated in an antagonistic role regulating overt wound closure and promoting ordered dermal remodeling. A mutant form of TGFβ3 (mutTGFβ3) was generated by ablating its bounden site for the latency‐associated TGFβ‐binding protein (LTBP‐1) [78]. A localized intradermal transduction using a lentiviral vector expressing the mutTGFβ3 in a mouse pare wounding model was demonstrated to reduce reepithelialization density and fibroblast/myofibroblast trans‐differentiation within the wound area. Both of which reduced scar tissue formation (Figure 2). Using a noninvasive imaging organisation, the kinetics of luciferase cistron expression was studied when delivered in an adenoviral vector (replication‐scarce adenovirus, Ad5). A elevation of gene expression occurred at seven days after commitment [79]. The esophageal cancer‐related gene‐4 (Ecrg4) delivering a viral‐mediated gene was evaluated in a cutaneous wound healing model [eighty]. Both Ecrg4 mRNA and its protein product were localized to the epidermis, dermis, and hair follicles of good for you mouse peel.

5.2. Nonviral vectors in cistron delivery

Gene delivery using adenoviral vectors in tissue regeneration is hindered by a brusque duration of transgene expression. A fibrin scaffold was used to enhance delivery of the adenovirus to a wound site, precluding the need for high repeated doses [81]. An anti‐fibrotic interfering RNA (RNAi) delivery system using exogenous microRNA (miR)‐29B was proposed to modulate ECM remodeling post-obit cutaneous injury. A collagen scaffold was used as the carrier of (miR)‐29B. The mRNA expressions of collagen type I and collagen blazon III were reduced up to two weeks subsequently fibroblasts civilisation. In vivo evaluation in full‐thickness wounds treated with miR‐29B commitment revealed that collagen blazon Iii/I ratio and matrix metalloproteinase (MMP)‐8 to TIMP‐1 ratio were improved [82]. Porous (100 and 60 μm) and nonporous (n‐pore) hyaluronic acrid‐MMP hydrogels with encapsulated reporter (pGFPluc) or proangiogenic (pVEGF) plasmids are used as a scaffold‐mediated gene delivery [83]. Alginate‐DNA gels were used to treat diabetic wounds, which provided sustained release of bioactive factors, such every bit neuropeptides and VEGF [13]. Silver nanoparticles (AgNPs) can be further augmented for cistron commitment applications. The biofunctionalized stable AgNPs with good DNA‐bounden ability for efficient transfection and minimal toxicity were developed [84]. Polyethylene glycol (PEG)‐stabilized chitosan‐chiliad‐polyacrylamide was used to modify AgNPs. To enhance the efficiency of gene transfection, the Arg‐Gly‐Asp‐Ser (RGDS) peptide was immobilized on the surface of AgNPs. The transfection efficiency of AgNPs increased significantly later on immobilization of the RGDS peptide reaching up to 42 ± four% and 30 ± 3% in HeLa and A549 cells, respectively. The transfection efficiency was significantly college than 34 ± 3% and 23 ± 2%, respectively, with the use of polyethylenimine (PEI, 25 kDa).

For treating diabetic patients with a threat of limb amputations, genes of diverse growth factors have been proposed in delivery systems. A elementary nonviral factor delivery using minicircle plasmid DNA encoding VEGF was combined with an arginine‐grafted cationic dendrimer PAM‐RG4 [85]. Mouse ASCs were transfected with DNA plasmid encoding VEGF or green fluorescent protein (GFP) using biodegradable poly (β‐amino) esters (PBAE). Cells transfected with Lipofectamine™ 2000, a commercially available transfection reagent, were included as controls. ASCs transfected using PBAEs showed an enhanced transfection efficiency and 12–xv‐folds higher VEGF product compared with the controls (* P  < 0.05) [86]. Keratinocyte growth factor‐1 (KGF‐1) Deoxyribonucleic acid was delivered using NTC8385‐VA1 plasmid, a novel minimalized, antibiotic‐gratis Deoxyribonucleic acid expression vector [87].

Figure iii.

(A) Fourth dimension course of nanoneedles incubated in cell‐civilization medium at 37°C. Scale bar = ii μm. (B) Nanoneedles mediate neovascularization in wound healing. (C) The number of nodes in the vasculature per millimeter square. (D) Within each field of view caused for untreated control, intramuscular injection (IM), and nanoinjection. P < 0.05, P < 0.01, P < 0.001.

Deoxyribonucleic acid‐incorporated electrospun nanofibrous matrix was fabricated to control the release of DNA in response to loftier concentration of MMPs (matrix metalloproteinases) such as diabetic ulcers [88]. High efficiency and minimal toxicity in vitro accept been demonstrated that can be used for an intracellular delivery of nucleic acids by using nanoneedles [89]. Biodegradable nanoneedles were fabricated past metal‐assisted chemic etching of silicon. These nanoneedles mediated the in situ delivery of an angiogenic cistron, VEGF165, and triggered the patterned formation of new blood vessels. The nanoneedles were designed for extremely localized delivery to a few superficial layers of cells (ii‐dimensional patterning). This factor delivery tin can admission the cytosol to co‐deliver Dna and siRNA with an efficiency greater than 90%. In vivo studies show that the nanoneedles transfected the VEGF165 gene, improved wound healing and scar‐tissue remodeling, and induced sustained neovascularization and a localized sixfold increment in blood perfusion in the target region of the muscle (Figure 3). This confined intracellular commitment has the potential to target specific exposed areas within a tissue, further reduce the invasiveness of the injection, and limit the impact on the overall structure of the tissue.

Advertizement

half-dozen. Regulatory considerations

The major concerns of commercialization of drug/protein/cell/gene delivery wound dressings are the complicated registration process, specifically regulatory approval, protocol consideration, and clinical trial process. Among all the parameters of commitment wound dressings, the type and source of the materials (e.one thousand., human and animal origin) are critical to the regulatory approval process. A product composed of two or more regulated components, that is, drug/device, biologic/device, drug/biologic, or drug/device/biologic, that are physically, chemically, or otherwise combined or mixed and produced as a single entity is defined as a combination production [90]. The FDA (Food and Drug Administration, Usa) regulation of a combination production (e.g., delivery system for wound healing) is mainly adamant by the component with the principal mode of action. According to the classification of the product, the clinical trials (for premarket blessing, PMA) must provide valid scientific show of safety and efficacy to support the indicated use of the wound healing delivery systems. Mostly, preclinical studies contain toxicity studies and animal model evaluations. Delivery systems of drugs, bioactive proteins, cells, and genes in wound healing and nanomedicine should test their biocompatibility according to ISO 10993, including dermal irritation, dermal sensitization, cytotoxicity, astute systemic toxicity, hemocompatibility/hemolysis, pyrogenicity, mutagenicity studies, subchronic toxicity, chronic toxicity, and immunogenic potential [91]. Good clinical practices (GCPs) are the standards for designing, conducting, recording, and reporting clinical trials required for Form Iii medical devices.

For example, autologous stem cells are under clinical trial and are effective in ulcer healing and angiogenesis. However, translating commitment of stem jail cell application in in vitro and in vivo experiments from animal models to human clinical trials is still in its infancy. Preclinical studies suggest that jail cell delivery systems represent an effective and safe therapeutic strategy in the treatment of nonhealing wounds. More than clinical studies on man subjects, including amend data direction of the patients and long‐term follow‐upwardly of the patients' conditions, are necessary. Improved stem cell delivery vehicles in large‐scale human clinical trials may be promising for diabetics with pes ulcers. There are no serious complications or side furnishings, but its therapeutic mechanisms, effects, and standardization still require farther research [92]. While commitment system‐based products offering increasingly important strategies for managing complex wounds, potential drawbacks include the risks of infectious amanuensis transfer and immunological rejection. The manufacturing process, ship, and storage of commitment systems in wound healing are major toll implications; thus, their current clinical use remains express [93]. Many current clinical trials are placing a high accent on addressing condom problems in all stem cell therapies, including stem prison cell delivery in wound healing [94]. The serious adverse furnishings of stem cell delivery are mainly allowed response and tumorigenic potential. Delivery systems used in cell therapy embrace four main approaches, which are systemic assistants, injection, topical, and local deliveries. Localized commitment of cells in wound healing is an optimal delivery arroyo for wound treatments [95]. Nonimmunogenic, nontoxic, biodegradable, and biocompatible biomaterials have been developed as carriers of stem cells that tin can protect cells and improve wound healing. Notwithstanding, clinical utilise of stalk cells, for example, allogeneic EPCs, is currently inhibited by the run a risk of immunogenicity and tumorigenicity. To modulate the immune response, mesenchymal stromal cells or umbilical string blood is already used in clinical trials, simply definitive results are notwithstanding pending. MSCs are known to exist hypoimmunogenic [96]. Current challenges are standardized and quality‐controlled prison cell therapy, the differentiation of MSCs to unwanted tissue, and potential tumorigenicity [94]. MSCs have been applied clinically for the handling of diabetic wounds. Long in vitro expansion time and multiple handling procedures are barriers for its clinical application and increase the chances of infection [97]. Autologous induced pluripotent stem cells are nonimmunogenic and can be a promising jail cell source used in wound healing [98]. Past comparison, clinical use of allogeneic cells is more than complex and requires additional regulatory, legal, and condom hurdles to exist overcome [99]. All things considered, the future prospects for the utilization of both autologous and allogeneic cells in cell delivery systems are vivid. In the The states, there are three regulatory processes for the registration of wound healing commitment systems [100]. Only wound dressing with lower complexity and take chances that is essentially equivalent to a marketed "predicate" device may be cleared through the 510(k) premarket notification process. In some other words, those types of wound dressings are classified equally Course I medical device. Clinical data are typically not needed for 510(thou) clearance of Class 2 medical devices. Higher‐risk Course Three medical devices typically require premarket approving (PMA). In summary, the regulatory processes are depending on multiple factors including the device's classification, the availability of a substantially equivalent predicate, and the level of risk. Before commercialization, investigational devices maybe clinically investigated within the USA through the investigational device exemption (IDE) process, which is a request to conduct clinical research on an investigational device with "significant" risk in the U.s. .

User fees are required with the submissions of 510(k) premarket notifications and PMA awarding in the Usa . Recently, Health Canada released a consultation document that discusses the price recovery (user fee) framework which shows the ground for accountability at Wellness Canada for the review procedure [101]. Substantially, the fees "guarantee" a certain level of service from Health Canada—for instance, specifying the target number of days in which Health Canada will process different types of applications. If the targets are not met, that is, if "operation" does non meet the established standard, the entity beingness charged the user fee volition have their time to come fees reduced past a respective corporeality. Providing a framework for registration approval globally of delivery wound dressings would translate those delivery systems studied from the laboratory investigation stage to clinical use, which will benefit patients' quality of life.

Advertising

7. Conclusions

In the past few decades, many wound dressings and skin substitutes have been adult to treat skin loss and wounds. Delivery systems have been proven to better wound healing and pare tissue regeneration. Polymeric microspheres and nanospheres, nanoparticles, nanofibrous structures, hydrogels, and scaffolds have been developed to deliver drugs to wound sites, overcoming the challenges caused by antibody‐resistant microbial infections. Controlled release of drug delivery systems has been of increasing interest, also as the applications of nanotechnology and biomaterial scaffolds. Growth factor and peptide commitment systems applied in skin wound healing assist in the regeneration of tissue, reduction of scarring, and reconstruction of blood capillaries (neovascularization). Keratinocytes, fibroblasts, endothelial cells, mesenchymal stem cells, adipose‐derived stalk cells, and endothelial progenitor cells studied in delivery systems have keen promise in chronic wounds and diabetic ulcers. Factor therapies now in clinical trials and the discovery of biodegradable polymers, fibrin meshes, and human collagen serving as potential commitment systems may soon exist available to clinical wound direction. However, regeneration of peripheral fretfulness is seldom reported. Looking toward the futurity, these delivery wound healing products may be able to reach the replacement and regeneration of more normal skin; to gain localized delivery to wound site; to heal severe burns, chronic and complex wounds; to control the release of drugs, growth factors, and cells; and to silence genes.

References

  1. ane. Wan WK, Yang L, Padavan DT. Employ of degradable and nondegradable nanomaterials for controlled release. Nanomedicine (Lond). 2007 Aug;2(4):483‐509. DOI: ten.2217/17435889.2.iv.483
  2. 2. Hurtley S, Hines PJ, Mueller KL, Culotta E. From bench to bedside. Science. 2014 Nov 21; 346(6212):932–3. DOI: x.1126/science.346.6212.932
  3. 3. Kamolz LP, Griffith 1000, Finnerty C, Kasper C. Skin regeneration, repair, and reconstruction. BioMed Research International. 2015 January i; 2015. DOI: 10.1155/2015/892031
  4. four. Orgill DP, Blanco C, editors. Biomaterials for treating skin loss. Cambridge: Woodhead Publishing Limited; 2009 Jan 28.
  5. 5. Gurtner GC, Werner South, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008 May 15; 453(7193):314–21. DOI:10.1038/nature07039
  6. 6. Teo EY, Ong SY, Chong MS, Zhang Z, Lu J, Moochhala Southward, Ho B, Teoh SH. Polycaprolactone‐based fused degradation modeled mesh for delivery of antibacterial agents to infected wounds. Biomaterials. 2011 Jan 31; 32(1):279–87. DOI:10.1016/j.biomaterials.2010.08.089
  7. 7. Singh B, Sharma S, Dhiman A. Blueprint of antibody containing hydrogel wound dressings: biomedical backdrop and histological report of wound healing. International Journal of Pharmaceutics. 2013 Nov 30; 457(1):82–91. DOI: ten.1016/j.ijpharm.2013.09.028
  8. viii. Sacco P, Travan A, Borgogna K, Paoletti South, Marsich E. Silvery‐containing antimicrobial membrane based on chitosan‐TPP hydrogel for the treatment of wounds. Journal of Materials Scientific discipline: Materials in Medicine. 2015 Mar 1; 26(three):1–2. DOI: x.1007/s10856‐015‐5474‐7
  9. 9. Sun BK, Siprashvili Z, Khavari PA. Advances in skin grafting and handling of cutaneous wounds. Science. 2014 Nov 21; 346(6212):941–5. DOI: 10.1126/science.1253836
  10. 10. Hanson SE, Kleinbeck KR, Cantu D, Kim J, Bentz ML, Faucher LD, Kao WJ, Hematti P. Local delivery of allogeneic os marrow and adipose tissue-derived mesenchymal stromal cells for cutaneous wound healing in a porcine model. Journal of Tissue Engineering and Regenerative Medicine. 2013 Feb 1. DOI: 10.1002/term.1700.
  11. 11. Peng Y, Xuan M, Zou J, Liu H, Zhuo Z, Wan Y, Cheng B. Freeze‐dried rat bone marrow mesenchymal stem jail cell paracrine factors: a simplified novel fabric for skin wound therapy. Tissue Technology Part A. 2014 Dec ix; 21(5–vi):1036–46. DOI: ten.1089/ten.TEA.2014.0102
  12. 12. Nie C, Zhang G, Yang D, Liu T, Liu D, Xu J, Zhang J. Targeted commitment of adipose-derived stem cells via acellular dermal matrix enhances wound repair in diabetic rats. Journal of Tissue Engineering and Regenerative Medicine. 2015 Mar 1; 9(three):224–35. DOI: 10.1002/term.1622
  13. 13. Tellechea A, Silva EA, Min J, Leal EC, Auster ME, Pradhan‐Nabzdyk L, Shih W, Mooney DJ, Veves A. Alginate and DNA gels are suitable delivery systems for diabetic wound healing. The International Journal of Lower Extremity Wounds. 2015 Jun 1:1534734615580018. DOI: ten.1177/1534734615580018
  14. fourteen. Kobsa S, Kristofik NJ, Sawyer AJ, Bothwell AL, Kyriakides TR, Saltzman WM. An electrospun scaffold integrating nucleic acid delivery for handling of full‐thickness wounds. Biomaterials. 2013 May 31; 34(15):3891–901. DOI: 10.1016/j.biomaterials.2013.02.016
  15. fifteen. Narang As, Chang RK, Hussain MA. Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems. Journal of Pharmaceutical Sciences. 2013 Nov ane; 102(xi):3867–82. DOI: 10.1002/jps.23691
  16. xvi. Gainza G, Villullas Due south, Pedraz JL, Hernandez RM, Igartua M. Advances in drug commitment systems (DDSs) to release growth factors for wound healing and skin regeneration. Nanomedicine: Nanotechnology, Biological science and Medicine. 2015 Aug 31; 11(6):1551–73. DOI: 10.1016/j.nano.2015.03.002
  17. 17. Katti DS, Robinson KW, Ko FK, Laurencin CT. Bioresorbable nanofiber-based systems for wound healing and drug commitment: optimization of fabrication parameters. Periodical of Biomedical Materials Enquiry Role B: Practical Biomaterials. 2004 Aug 15;70(ii):286–96. DOI: 10.1002/jbm.b.30041
  18. xviii. Elsner JJ, Zilberman Chiliad. Antibiotic‐eluting bioresorbable composite fibers for wound healing applications: microstructure, drug delivery and mechanical properties. Acta Biomaterialia. 2009 Oct 31;5(8):2872–83. DOI: 10.1016/j.actbio.2009.04.007
  19. nineteen. Hima Bindu TV, Vidyavathi M, Kavitha Thou, Sastry TP, Suresh kumar RV. Grooming and evaluation of ciprofloxacin loaded chitosan–gelatin blended films for wound healing action. International Journal of Drug Delivery. 2010; 2(ii):173–82. DOI: 10.5138/ijdd.2010.0975.0215.02027
  20. 20. Rouabhia K, Asselin J, Tazi N, Messaddeq Y, Levinson D, Zhang Z. Production of biocompatible and antimicrobial bacterial cellulose polymers functionalized by RGDC grafting groups and gentamicin. ACS Applied Materials & Interfaces. 2014 Jan fourteen;6(iii):1439–46. DOI: 10.1021/am4027983
  21. 21. Nagiah Northward, Ramanathan 1000, Sobhana Fifty, Sivagnanam UT, Srinivasan NT. Poly (vinyl alcohol) microspheres sandwiched poly (iii‐hydroxybutyric acrid) electrospun fibrous scaffold for tissue technology and drug delivery. International Periodical of Polymeric Materials and Polymeric Biomaterials. 2014 Jul 24;63(11):583–5. DOI: 10.1080/00914037.2013.854230
  22. 22. Li R, Zhang 10, Zhang Q, Liu H, Rong J, Tu M, Zeng R, Zhao J. β-Cyclodextrin-conjugated hyaluronan hydrogel as a potential drug sustained delivery carrier for wound healing. Journal of Practical Polymer Science. 2016 Mar five;133(9):43072(ane–8). DOI: ten.1002/app.43072
  23. 23. Li Y, Liu G, Wang X, Hu J, Liu South. Enzyme-responsive polymeric vesicles for bacterial strain-selective delivery of antimicrobial agents. Angewandte Chemie International Edition England. 2016 Jan 26;55(5):1760‐4. DOI: ten.1002/anie.201509401
  24. 24. Atiyeh BS, Costagliola Thousand, Hayek SN, Dibo SA. Effect of silverish on fire wound infection control and healing: review of the literature. Burns. 2007 Mar 31;33(ii):139–48. DOI: 10.1016/j.burns.2006.06.010
  25. 25. Khampieng T, Brikshavana P, Supaphol P. Argent nanoparticle‐embedded poly (vinyl pyrrolidone) hydrogel dressing: gamma‐ray synthesis and biological evaluation. Journal of Biomaterials Scientific discipline, Polymer Edition. 2014 May 24;25(8):826–42. DOI: ten.1080/09205063.2014.910154
  26. 26. Oliveira RN, Rouzé R, Quilty B, Alves GG, Soares GD, Thiré RM, McGuinness GB. Mechanical backdrop and in vitro characterization of polyvinyl booze‐nano‐silver hydrogel wound dressings. Interface Focus. 2014 February half-dozen;iv(1):20130049. DOI: 10.1098/rsfs.2013.0049
  27. 27. Shankar S, Jaiswal L, Aparna RS, Prasad RG, Kumar GP, Manohara CM. Wound healing potential of green synthesized silver nanoparticles prepared fromLansium domesticumfruit peel extract. Materials Limited. 2015 Mar one;5(two):159–64. DOI: 10.1166/mex.2015.1225
  28. 28. Mohiti‐Asli M, Pourdeyhimi B, Loboa EG. Skin tissue engineering science for the infected wound site: biodegradable PLA nanofibers and a novel approach for silvery ion release evaluated in a 3D coculture organization of keratinocytes andStaphylococcus aureus. Tissue Engineering Part C: Methods. 2014 Mar 17;20(10):790–7. DOI: ten.1089/ten.tec.2013.0458
  29. 29. Patrulea 5, Ostafe V, Borchard G, Jordan O. Chitosan as a starting textile for wound healing applications. European Periodical of Pharmaceutics and Biopharmaceutics. 2015 Nov xxx;97:417–26. DOI: 10.1016/j.ejpb.2015.08.004
  30. thirty. Madhumathi Thou, Kumar PS, Abhilash S, Sreeja V, Tamura H, Manzoor M, Nair SV, Jayakumar R. Development of novel chitin/nanosilver composite scaffolds for wound dressing applications. Journal of Materials Scientific discipline: Materials in Medicine. 2010 Feb 1;21(2):807–13. DOI: x.1007/s10856‐009‐3877‐z
  31. 31. Banerjee J, Ghatak PD, Roy South, Khanna S, Hemann C, Deng B, Das A, Zweier JL, Wozniak D, Sen CK. Argent‐zinc redox‐coupled electroceutical wound dressing disrupts bacterial biofilm. PLoS Ane. 2015 Mar 24;10(three):e0119531. DOI: 10.1371/journal.pone.0119531
  32. 32. Chen Ten, Peng LH, Shan YH, Li N, Wei Westward, Yu L, Li QM, Liang WQ, Gao JQ. Astragaloside 4‐loaded nanoparticle‐enriched hydrogel induces wound healing and anti‐scar activity through topical commitment. International Periodical of Pharmaceutics. 2013 Apr fifteen;447(1):171–81. DOI: 10.1016/j.ijpharm.2013.02.054
  33. 33. Yallapu MM, Nagesh PK, Jaggi Grand, Chauhan SC. Therapeutic applications of curcumin nanoformulations. The AAPS Journal. 2015 November ane;17(6):1341–56. DOI: 10.1208/s12248‐015‐9811‐z
  34. 34. Dai M, Zheng X, Xu X, Kong X, Li X, Guo Chiliad, Luo F, Zhao X, Wei YQ, Qian Z. Chitosan‐alginate sponge: grooming and application in curcumin commitment for dermal wound healing in rat. BioMed Enquiry International. 2009 November 11;2009. DOI: x.1155/2009/595126
  35. 35. Krausz AE, Adler BL, Cabral V, Navati M, Doerner J, Charafeddine RA, Chandra D, Liang H, Gunther L, Clendaniel A, Harper S. Curcumin‐encapsulated nanoparticles as innovative antimicrobial and wound healing agent. Nanomedicine: Nanotechnology, Biology and Medicine. 2015 Jan 31;11(1):195–206. DOI: 10.1016/j.nano.2014.09.004
  36. 36. Huang Fifty, Chen 10, Nguyen TX, Tang H, Zhang L, Yang Grand. Nano‐cellulose 3D‐networks as controlled‐release drug carriers. Journal of Materials Chemistry B. 2013;one(23):2976–84. DOI: 10.1039/c3tb20149j
  37. 37. Trovatti Due east, Freire CS, Pinto PC, Almeida IF, Costa P, Silvestre AJ, Neto CP, Rosado C. Bacterial cellulose membranes applied in topical and transdermal delivery of lidocaine hydrochloride and ibuprofen: in vitro diffusion studies. International Periodical of Pharmaceutics. 2012 Oct one;435(1):83–vii. DOI: ten.1016/j.ijpharm.2012.01.002
  38. 38. Duscher D, Neofytou E, Wong VW, Maan ZN, Rennert RC, Inayathullah M, Januszyk Yard, Rodrigues M, Malkovskiy AV, Whitmore AJ, Walmsley GG. Transdermal deferoxamine prevents pressure‐induced diabetic ulcers. Proceedings of the National University of Sciences. 2015 Jan 6;112(1):94–ix. DOI: 10.1073/pnas.1413445112
  39. 39. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic Grand. Growth factors and cytokines in wound healing. Wound Repair and Regeneration. 2008 Sep 1;16(5):585–601. DOI: 10.1111/j.1524‐475X.2008.00410.x
  40. 40. Koria P. Delivery of growth factors for tissue regeneration and wound healing. BioDrugs. 2012 Jun 1;26(3):163–75. DOI: 10.2165/11631850‐000000000‐0000
  41. 41. Geer DJ, Swartz DD, Andreadis ST. Biomimetic commitment of keratinocyte growth factor upon cellular need for accelerated wound healing in vitro and in vivo. The American Journal of Pathology. 2005 Dec 31;167(6):1575–86. DOI: 10.1016/S0002‐9440(10)61242‐four
  42. 42. Yao C, Yao P, Wu H, Zha Z. Acceleration of wound healing in traumatic ulcers by absorbable collagen sponge containing recombinant basic fibroblast growth factor. Biomedical Materials. 2006 Mar xv;1(one):33. DOI:x.1088/1748‐6041/i/1/005
  43. 43. Hardwicke J, Ferguson EL, Moseley R, Stephens P, Thomas DW, Duncan R. Dextrin–rhEGF conjugates every bit bioresponsive nanomedicines for wound repair. Periodical of Controlled Release. 2008 Sep 24;130(3):275–83. DOI: x.1016/j.jconrel.2008.07.023
  44. 44. Kulkarni A, Diehl‐Jones W, Ghanbar S, Liu South. Layer‐by‐layer associates of epidermal growth factors on polyurethane films for wound closure. Journal of Biomaterials Applications. 2014 Aug 1;29(ii):278–90. DOI: 10.1177/0885328214523058
  45. 45. Picheth GF, Sierakowski MR, Woehl MA, Ono Fifty, Cofré AR, Vanin LP, Pontarolo R, De Freitas RA. Lysozyme-triggered epidermal growth factor release from bacterial cellulose membranes controlled by smart nanostructured films. Journal of Pharmaceutical Sciences. 2014 Dec one;103(12):3958–65. DOI: x.1002/jps.24205
  46. 46. Johnson NR, Wang Y. Controlled delivery of heparin‐bounden EGF‐like growth factor yields fast and comprehensive wound healing. Journal of Controlled Release. 2013 Mar 10;166(two):124–ix. DOI: x.1016/j.jconrel.2012.11.004
  47. 47. Yenilmez E, Basaran Eastward, Arslan R, Berkman MS, Güven UM, Bayçu C, Yazan Y. Chitosan gel formulations containing egg yolk oil and epidermal growth cistron for dermal burn down handling. Die Pharmazie: An International Journal of Pharmaceutical Sciences. 2015 February 2;70(2):67–73. DOI: x.1691/ph.2015.4126
  48. 48. Nunes QM, Li Y, Sun C, Kinnunen TK, Fernig DG. Fibroblast growth factors as tissue repair and regeneration therapeutics. PeerJ. 2016 Jan 12;four:e1535. DOI: 10.7717/peerj.1535
  49. 49. Park HJ, Lee S, Kang KH, Heo CY, Kim JH, Yang HS, Kim BS. Enhanced random pare flap survival by sustained delivery of fibroblast growth gene 2 in rats. ANZ Periodical of Surgery. 2013 May 1;83(5):354–eight. DOI: 10.1111/j.1445‐2197.2012.06194.x
  50. 50. Fabiilli ML, Wilson CG, Padilla F, Martín‐Saavedra FM, Fowlkes JB, Franceschi RT. Acoustic droplet–hydrogel composites for spatial and temporal control of growth cistron delivery and scaffold stiffness. Acta Biomaterialia. 2013 Jul 31;ix(seven):7399–409. DOI: 10.1016/j.actbio.2013.03.027
  51. 51. Li B, Davidson JM, Guelcher SA. The effect of the local delivery of platelet‐derived growth factor from reactive two‐component polyurethane scaffolds on the healing in rat skin excisional wounds. Biomaterials. 2009 Jul 31;30(xx):3486–94. DOI: 10.1016/j.biomaterials.2009.03.008
  52. 52. Zavan B, Vindigni V, Vezzù Grand, Zorzato G, Luni C, Abatangelo Thousand, Elvassore N, Cortivo R. Hyaluronan based porous nano‐particles enriched with growth factors for the treatment of ulcers: a placebo‐controlled report. Journal of Materials Scientific discipline: Materials in Medicine. 2009 Jan 1;20(i):235–47. DOI: x.1007/s10856‐008‐3566‐3
  53. 53. Rabbany SY, Pastore J, Yamamoto K, Miller T, Rafii Southward, Aras R, Penn Grand. Continuous commitment of stromal cell‐derived factor‐one from alginate scaffolds accelerates wound healing. Cell Transplantation. 2010 Apr ane;19(4):399–408. DOI: 10.3727/096368909X481782
  54. 54. Lin YK, Chen KH, Ou KL, Liu M. Effects of dissimilar extracellular matrices and growth factor immobilization on biodegradability and biocompatibility of macroporous bacterial cellulose. Periodical of Bioactive and Compatible Polymers. 2011 Sep 1;26(5):508–18. DOI: x.1177/0883911511415390
  55. 55. Ribeiro MP, Morgado PI, Miguel SP, Coutinho P, Correia IJ. Dextran‐based hydrogel containing chitosan microparticles loaded with growth factors to exist used in wound healing. Materials Science and Engineering science: C. 2013 Jul i;33(five):2958–66. DOI: x.1016/j.msec.2013.03.025
  56. 56. Jin Thou, Prabhakaran MP, Kai D, Ramakrishna S. Controlled release of multiple epidermal induction factors through cadre–crush nanofibers for skin regeneration. European Journal of Pharmaceutics and Biopharmaceutics. 2013 Nov xxx;85(3):689–98. DOI: 10.1016/j.ejpb.2013.06.002
  57. 57. Almquist BD, Castleberry SA, Sun JB, Lu AY, Hammond PT. Combination growth factor therapy via electrostatically assembled wound dressings improves diabetic ulcer healing in vivo. Advanced Healthcare Materials. 2015 October 1;4(14):2090–9. DOI: x.1002/adhm.201500403
  58. 58. Eisenhardt M, Dobler D, Schlupp P, Schmidts T, Salzig M, Vilcinskas A, Salzig D, Czermak P, Keusgen M, Runkel F. Development of an insect metalloproteinase inhibitor drug carrier system for application in chronic wound infections. Journal of Chemist's shop and Pharmacology. 2015 November 1;67(xi):1481–91. DOI: ten.1111/jphp.12452
  59. 59. Chereddy KK, Her CH, Comune M, Moia C, Lopes A, Porporato PE, Vanacker J, Lam MC, Steinstraesser Fifty, Sonveaux P, Zhu H. PLGA nanoparticles loaded with host defense force peptide LL37 promote wound healing. Journal of Controlled Release. 2014 Nov 28;194:138–47. DOI: 10.1016/j.jconrel.2014.08.016
  60. 60. Babavalian H, Latifi AM, Shokrgozar MA, Bonakdar South, Mohammadi Southward, Moghaddam MM. Analysis of healing outcome of alginate sulfate hydrogel dressing containing antimicrobial peptide on wound infection caused by methicillin‐resistantStaphylococcus aureus. Jundishapur Journal of Microbiology. 2015 Sep;eight(9). DOI: x.5812/jjm.28320
  61. 61. Zhang M, Rehman J, Malik AB. Endothelial progenitor cells and vascular repair. Current Opinion in Hematology. 2014 May;21(iii):224. DOI: 10.1097/MOH.0000000000000041.
  62. 62. Xu G, Cantu DA, Fu Y, Kim J, Zheng X, Hematti P, Kao WJ. Thiol‐ene Michael‐type formation of gelatin/poly (ethylene glycol) biomatrices for three‐dimensional mesenchymal stromal/stalk prison cell administration to cutaneous wounds. Acta Biomaterialia. 2013 November 30;nine(xi):8802–xiv. DOI: 10.1016/j.actbio.2013.06.021
  63. 63. Sánchez‐Sánchez R, Brena‐Molina A, Martínez‐López V, Melgarejo‐Ramírez Y, de Dios LT, Gómez‐García R, de Lourdes Reyes‐Frías M, Rodríguez‐Rodríguez L, Garciadiego‐Cázares D, Lugo‐Martínez H, Ibarra C. Generation of 2 biological wound dressings as a potential delivery system of homo adipose‐derived mesenchymal stem cells. Asaio Journal. 2015 Nov;61(6):718. DOI: 10.1097/MAT.0000000000000277
  64. 64. Wahl EA, Fierro FA, Peavy TR, Hopfner U, Dye JF, Machens HG, Egaña JT, Schenck TL. In vitro evaluation of scaffolds for the delivery of mesenchymal stem cells to wounds. BioMed Research International. 2015 Oct 4;2015:1. DOI: 10.1155/2015/108571
  65. 65. Rustad KC, Wong VW, Sorkin Chiliad, Glotzbach JP, Major MR, Rajadas J, Longaker MT, Gurtner GC. Enhancement of mesenchymal stem cell angiogenic capacity and stemness by a biomimetic hydrogel scaffold. Biomaterials. 2012 January 31;33(1):80–90. DOI: x.1016/j.biomaterials.2011.09.041
  66. 66. Zebardast N, Lickorish D, Davies JE. Human umbilical string perivascular cells (HUCPVC) A mesenchymal jail cell source for dermal wound healing. Organogenesis. 2010 Oct 1;6(4):197–203. DOI: 10.4161/org6.iv.12393
  67. 67. Skardal A, Mack D, Kapetanovic Eastward, Atala A, Jackson JD, Yoo J, Soker S. Bioprinted amniotic fluid‐derived stalk cells accelerate healing of large skin wounds. Stem Cells Translational Medicine. 2012 Nov;1(11):792. DOI: 10.5966/sctm.2012‐0088
  68. 68. Kim KL, Han DK, Park Thousand, Song SH, Kim JY, Kim JM, Ki HY, Yie SW, Roh CR, Jeon ES, Kim DK. Enhanced dermal wound neovascularization by targeted delivery of endothelial progenitor cells using an RGD‐thou‐PLLA scaffold. Biomaterials. 2009 Aug 31;30(22):3742–viii. DOI: ten.1016/j.biomaterials.2009.03.053
  69. 69. O'Loughlin A, Kulkarni Chiliad, Vaughan EE, Creane M, Liew A, Dockery P, Pandit A, O'Brien T. Autologous circulating angiogenic cells treated with osteopontin and delivered via a collagen scaffold heighten wound healing in the alloxan‐induced diabetic rabbit ear ulcer model. Stalk cell Enquiry & Therapy. 2013 Dec 1;iv(6):i–four. DOI: ten.1186/scrt388
  70. 70. Shingyochi Y, Orbay H, Mizuno H. Adipose‐derived stem cells for wound repair and regeneration. Practiced Stance on Biological Therapy. 2015 Sep 2;15(nine):1285–92. DOI: 10.1517/14712598.2015.1053867
  71. 71. Altman AM, Yan Y, Matthias N, Bai X, Rios C, Mathur AB, Song YH, Alt EU. IFATS collection: human adipose-derived stem cells seeded on a silk fibroin-chitosan scaffold enhance wound repair in a murine soft tissue injury model. Stem Cells. 2009 Jan ane;27(i):250–8. DOI: x.1634/stemcells.2008‐0178
  72. 72. Hassan West, Dong Y, Wang W. Encapsulation and 3D culture of human adipose‐derived stalk cells in an in‐situ crosslinked hybrid hydrogel equanimous of PEG‐based hyperbranched copolymer and hyaluronic acid. Stem Jail cell Inquiry & Therapy. 2013 Mar 21;4(2):32. DOI: x.1186/scrt182
  73. 73. Zeng Y, Zhu L, Han Q, Liu W, Mao 10, Li Y, Yu Due north, Feng S, Fu Q, Wang X, Du Y. Preformed gelatin microcryogels as injectable cell carriers for enhanced skin wound healing. Acta Biomaterialia. 2015 Oct 1;25:291–303. DOI: 10.1016/j.actbio.2015.07.042
  74. 74. Bathany C, Park J, Cho YK, Takayama S. Dehydrated aqueous ii‐phase organisation micro‐domains retain their shape upon rehydration to allow patterned reagent delivery to cells. Journal of Materials Chemistry B. 2013;ane(44):6020–6. DOI: ten.1039/c3tb21004a
  75. 75. Masuda R, Mochizuki 1000, Hozumi K, Takeda A, Uchinuma East, Yamashina Due south, Nomizu Thousand, Kadoya Y. A novel cell-adhesive scaffold fabric for delivering keratinocytes reduces granulation tissue in dermal wounds. Wound Repair and Regeneration. 2009 January ane;17(one):127–35. DOI:10.1111/j.1524‐475X.2008.00450.ten
  76. 76. Nuutila One thousand, Peura Chiliad, Suomela S, Hukkanen M, Siltanen A, Harjula A, Vuola J, Kankuri East. Recombinant human being collagen Three gel for transplantation of autologous pare cells in porcine full-thickness wounds. Periodical of Tissue Applied science and Regenerative Medicine. 2015 Dec one;9(12):1386–93. DOI: 10.1002/term.1691
  77. 77. Sarett SM, Nelson CE, Duvall CL. Technologies for controlled, local commitment of siRNA. Journal of Controlled Release. 2015 Nov 28;218:94–113. DOI: 10.1016/j.jconrel.2015.09.066
  78. 78. Waddington SN, Crossley R, Sheard V, Howe SJ, Buckley SM, Coughlan L, Gilham DE, Hawkins RE, McKay TR. Gene delivery of a mutant TGFβ3 reduces markers of scar tissue germination after cutaneous wounding. Molecular Therapy. 2010 Dec 1;eighteen(12):2104–eleven. DOI: 10.1038/mt.2010.174
  79. 79. Peterson CY, Shaterian A, Borboa AK, Gonzalez AM, Potenza BM, Coimbra R, Eliceiri BP, Baird A. The noninvasive, quantitative, in vivo assessment of adenoviral‐mediated factor delivery in pare wound biomaterials. Biomaterials. 2009 December 31;thirty(35):6788–93. DOI: 10.1016/j.biomaterials.2009.07.069
  80. eighty. Shaterian A, Kao South, Chen 50, DiPietro LA, Coimbra R, Eliceiri BP, Baird A. The candidate tumor suppressor gene Ecrg4 every bit a wound terminating gene in cutaneous injury. Athenaeum of Dermatological Research. 2013 Mar 1;305(two):141–nine. DOI: 10.1007/s00403‐012‐1276‐7
  81. 81. Breen A, Dockery P, O'Brien T, Pandit A. Fibrin scaffold promotes adenoviral gene transfer and controlled vector delivery. Periodical of Biomedical Materials Research Part A. 2009 Jun xv;89(4):876–84. DOI: ten.1002/jbm.a.32039
  82. 82. Monaghan Grand, Browne S, Schenke‐Layland Thousand, Pandit A. A collagen‐based scaffold delivering exogenous microRNA‐29b to attune extracellular matrix remodeling. Molecular Therapy. 2014 April ane;22(4):786–96. DOI: ten.1038/mt.2013.288
  83. 83. Tokatlian T, Cam C, Segura T. Porous hyaluronic acid hydrogels for localized nonviral DNA delivery in a diabetic wound healing model. Avant-garde Healthcare Materials. 2015 May one;4(7):1084–91. DOI: ten.1002/adhm.201400783
  84. 84. Sarkar K, Banerjee SL, Kundu PP, Madras M, Chatterjee K. Biofunctionalized surface‐modified silver nanoparticles for gene commitment. Journal of Materials Chemistry B. 2015;three(26):5266–76. DOI: 10.1039/c5tb00614g
  85. 85. Kwon MJ, An S, Choi Southward, Nam K, Jung HS, Yoon CS, Ko JH, Jun HJ, Kim TK, Jung SJ, Park JH. Effective healing of diabetic skin wounds by using nonviral gene therapy based on minicircle vascular endothelial growth factor DNA and a cationic dendrimer. The Periodical of Cistron Medicine. 2012 Apr 1;14(4):272–8. DOI: 10.1002/jgm.2618
  86. 86. Nauta A, Seidel C, Deveza L, Montoro D, Grova M, Ko SH, Hyun J, Gurtner GC, Longaker MT, Yang F. Adipose‐derived stromal cells overexpressing vascular endothelial growth factor accelerate mouse excisional wound healing. Molecular Therapy. 2013 Feb i;21(ii):445–55. DOI: ten.1038/mt.2012.234
  87. 87. Dou C, Lay F, Ansari AM, Rees DJ, Ahmed AK, Kovbasnjuk O, Matsangos AE, Du J, Hosseini SM, Steenbergen C, Fob‐Talbot K. Strengthening the skin with topical delivery of keratinocyte growth factor‐one using a novel DNA plasmid. Molecular Therapy. 2014 Apr;22(four):752. DOI: x.1038/mt.2014.2
  88. 88. Kim HS, Yoo HS. MMPs‐responsive release of Deoxyribonucleic acid from electrospun nanofibrous matrix for local gene therapy: in vitro and in vivo evaluation. Journal of Controlled Release. 2010 Aug 3;145(three):264–71. DOI: 10.1016/j.jconrel.2010.03.006
  89. 89. Chiappini C, De Rosa East, Martinez JO, Liu X, Steele J, Stevens MM, Tasciotti Due east. Biodegradable silicon nanoneedles delivering nucleic acids intracellularly induce localized in vivo neovascularization. Nature Materials. 2015 May 1;14(5):532–nine. DOI: 10.1038/NMAT4249
  90. 90. United States Government Lawmaking of Federal Regulations, Title 21 (21CFR), Function 3, Food and Drugs, Office of the Federal Register National Archives and Records Administration, U.s.a. Government Press Office, Washington, DC, 2015 Apr one.
  91. 91. ISO 10993, Biological Evaluation of Medical Devices. 4thursday ed. Geneva: International Standards Organisation; 2009 October 15.
  92. 92. Dash SN, Dash NR, Guru B, Mohapatra PC. Towards reaching the target: clinical four application of mesenchymal stem cells for diabetic foot ulcers. Rejuvenation Enquiry, Mary Ann Liebert, Inc, New Rochelle, New York, The states. 5 2014 Feb 1; 17(one):40-53. DOI: ten.1089/rej.2013.1467
  93. 93. Chaudhary C, Garg T. Scaffolds: a novel carrier and potential wound healer. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2015;32(4):277–321. DOI: x.1615/CritRevTherDrugCarrierSyst.2015011246
  94. 94. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stalk cells a potential therapeutic strategy for type one diabetes. Diabetes. 2008 Jul ane;57(seven):1759–67. DOI: 10.2337/db08‐0180
  95. 95. Duscher D, Barrera J, Wong VW, Maan ZN, Whittam AJ, Januszyk M, Gurtner GC. Stalk cells in wound healing: the future of regenerative medicine a mini‐review. Gerontology. 2015 May 29;62(2):216–25. DOI: 10.1159/000381877
  96. 96. Ezquer Atomic number 26, Ezquer ME, Parrau DB, Carpio D, Yañez AJ, Conget PA. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biological science of Blood and Marrow Transplantation. 2008 Jun 30;xiv(6):631–40. DOI: 10.1016/j.bbmt.2008.01.006
  97. 97. Yang M, Sheng L, Zhang TR, Li Q. Stalk prison cell therapy for lower extremity diabetic ulcers: where practise we stand?. BioMed Research International. 2013 Mar 18;2013:462179. DOI: x.1155/2013/462179
  98. 98. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Jail cell. 2006 Aug 25;126(4):663–76. DOI: 10.1016/j.cell.2006.07.024
  99. 99. Kirby GT, Mills SJ, Cowin AJ, Smith LE. Stem cells for cutaneous wound healing. BioMed Research International. 2015 Jun ii;2015. DOI: x.1155/2015/285869
  100. 100. Jarow JP, Baxley JH. Medical devices: Usa medical device regulation. Urologic Oncology: Seminars and Original Investigations, 2015 Mar 31; 33(3): 128–132. DOI: 10.1016/j.urolonc.2014.10.004
  101. 101. Alpert S. Toll Recovery and the Hereafter of the Medical Device Regulation Program in Canada. Health Law Review. 2008 May 1;16(3):73–78.

Submitted: December 2nd, 2015 Reviewed: April 18th, 2016 Published: Oct 12th, 2016

© 2016 The Author(s). Licensee IntechOpen. This chapter is distributed nether the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

bourgthowelf.blogspot.com

Source: https://www.intechopen.com/chapters/51353

Post a Comment for "Wound Healing Dressings and Drug Delivery Systems a Review"